Stocks · News reference
UBS analyst Lu Li maintains Myriad Genetics (NASDAQ:MYGN) with a Neutral and lowers the price target from $6 to $3.6.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Myriad Genetics (NASDAQ:MYGN) affirms FY2026 sales outlook from $770.000 million-$790.000 million to $770.000 million-$790.000 million vs $776.790 million estimate.
Myriad Genetics announced the promotion of Vishal Sikri to Executive Vice President - Commercial effective September 16, 2026, replacing departing Chief Commercial Officer Brian Donnelly. Sikri, who previously served as SVP of Product, brings molecular diagnostics and oncology expertise. The company reaffirmed its full-year 2026 financial guidance.
Filed: 2026-09-16 AccNo: 0000899923-26-000079 Size: 206 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
RH shares jumped 8.2% premarket after EPS beat estimates despite a revenue miss; Oracle and others gained, while OPTT and ZUMZ fell.